Comparison of Breast Acoustic CT and Automated Breast Ultrasound in Women With Unilateral Untreated Breast Cancer

November 13, 2026 updated by: Stanford University

Comparison of the Diagnostic Accuracy of Bilateral Whole Breast Ultrasound Using QT Imaging and Invenia Automated Breast Ultrasound (ABUS) [GE Healthcare] in Women With Unilateral Untreated Current Breast Cancer.

This study addresses an unmet need to improve the diagnostic accuracy of: 1. supplemental breast cancer screening with whole breast US and 2. the evaluation of disease extent in women with newly diagnosed breast cancer.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • California
      • Palo Alto, California, United States, 94304
        • Stanford University
        • Contact:
        • Principal Investigator:
          • Steven P Poplack, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Unilateral untreated breast cancer evaluated by breast MRI
  2. Participants' age range ≥18 years old
  3. Ability to understand and the willingness to provide written informed consent.
  4. Female gender
  5. Dense Breast composition
  6. Breast MRI available for reference comparison
  7. Able to undergo QT and ABUS imaging prior to definitive surgery or neoadjuvant therapy.

Exclusion Criteria:

  1. Prior mastectomy
  2. Bilateral breast cancer
  3. Concurrent use of investigational agents
  4. Active breast infection, open wound, or skin condition involving the breast that would interfere with imaging.
  5. Breast size or body habitus incompatible with QT or ABUS image acquisition. i. Breasts with cup size A through DDD. Up to 400lbs of patient weight is supported.
  6. Non-dense breast composition
  7. Pregnant
  8. Breast feeding
  9. Receipt of neoadjuvant chemotherapy, endocrine therapy, or radiation therapy before QT/ABUS imaging

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: QTI Breast Acoustic CT™ Scanner [QT Imaging] (QT), and Automated Breast Ultrasound (ABUS)

Each participant will undergo one (1) imaging examination using the investigational QT Scanner and one (1) imaging examination using the FDA-cleared Invenia™ Automated Breast Ultrasound System (ABUS).

QT: The scanner is an FDA-cleared imaging technology that uses transmission ultrasound to generate quantitative maps of breast tissue properties (e.g., speed of sound, absorption) as well as provides reflection ultrasound images. It is a non-invasive, non-ionizing imaging modality and does not involve administration of a drug or biologic. Each participant will undergo one (1) imaging examination using the QT Scanner for comparison with images obtained using automated breast ultrasound (ABUS)

ABUS is FDA-approved for both supplemental breast cancer screening in women with radiographically dense breast tissue, and for diagnostic breast ultrasound imaging. Each participant will undergo one ABUS imaging examination for comparison with images obtained using the investigational QT Scanner.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Additional Breast Cancer Lesions Detected
Time Frame: Baseline

The number of additional contralateral and ipsilateral breast cancer lesions detected using the QT scanner and ABUS as reported by study radiologists in women with dense breast tissue and newly diagnosed unilateral breast cancer.

Baseline
BI-RADS Assessment
Time Frame: Baseline

Radiologists' diagnostic assessment of contralateral and ipsilateral breast cancer lesions identified using the QT Scanner and ABUS, as measured using the Breast Imaging Reporting and Data System (BI-RADS) classification categories.

Baseline
Numerical Likelihood of Malignancy
Time Frame: Baseline

Radiologists will assess the likelihood of malignancy for contralateral and ipsilateral breast cancer lesions detected by QT Scanner and ABUS. Diagnostic confidence will be measured using the numerical likelihood-of-malignancy estimates assigned to identified lesions.

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Steven P Poplack, Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2029

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB-89405

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe